- Home
- PBYI vs STTK Comparison
PBYI vs STTK Comparison
Compare PBYI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- STTK
- Stock Information
- Founded
- PBYI 2010
- STTK 2016
- Country
- PBYI United States
- STTK United States
- Employees
- PBYI N/A
- STTK N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- STTK Health Care
- Exchange
- PBYI Nasdaq
- STTK Nasdaq
- Market Cap
- PBYI 164.3M
- STTK 37.6M
- IPO Year
- PBYI N/A
- STTK 2020
- Fundamental
- Price
- PBYI $3.56
- STTK $0.83
- Analyst Decision
- PBYI Strong Buy
- STTK Hold
- Analyst Count
- PBYI 1
- STTK 4
- Target Price
- PBYI $7.00
- STTK $3.00
- AVG Volume (30 Days)
- PBYI 299.1K
- STTK 410.6K
- Earning Date
- PBYI 07-31-2025
- STTK 07-31-2025
- Dividend Yield
- PBYI N/A
- STTK N/A
- EPS Growth
- PBYI 143.51
- STTK N/A
- EPS
- PBYI 0.77
- STTK N/A
- Revenue
- PBYI $232,709,000.00
- STTK $4,606,000.00
- Revenue This Year
- PBYI N/A
- STTK N/A
- Revenue Next Year
- PBYI N/A
- STTK N/A
- P/E Ratio
- PBYI $4.64
- STTK N/A
- Revenue Growth
- PBYI 2.68
- STTK 69.65
- 52 Week Low
- PBYI $2.23
- STTK $0.69
- 52 Week High
- PBYI $4.13
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- PBYI 56.71
- STTK 41.39
- Support Level
- PBYI $3.49
- STTK $0.77
- Resistance Level
- PBYI $3.65
- STTK $0.87
- Average True Range (ATR)
- PBYI 0.13
- STTK 0.08
- MACD
- PBYI 0.01
- STTK -0.02
- Stochastic Oscillator
- PBYI 75.80
- STTK 17.65
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.